On December 22, 2014, the FDA granted accelerated approval to nivolumab (OPDIVO; Bristol-Myers Squibb, New York, NY) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation is positive, a BRAF inhibitor [4]. Here, BRAF is linked to metastatic melanoma.